Mar, 2024
HANGZHOU, China, January 26, 2024 – HJB is excited to announce a major breakthrough in its Highly Intensified Continuous Bioprocessing (HiCB) platform. Utilizing its proprietary ExcelPro CHO™ cell culture medium, the HiCB platform has reached an impressive productivity of 8 g/L-day in intensified continuous perfusion, more than 15X increase over conventional fed-batch processes with the same cell line.
At 8 g/L-day volumetric productivity, a single 1,000-liter single-use bioreactor can produce over 130 kg of therapeutic proteins per 30-day perfusion run, equating to an annual output of 1.5 metric tons. This is more than sufficient to support multiple commercial products. This marks a significant advancement for HJB in biopharmaceutical production, maximizing output while significantly reducing production costs.
The HiCB platform is well-suited for a wide range of protein drugs, including stable and labile proteins, such as monoclonal, multi-specific antibodies, and recombinant proteins. By leveraging commercially available perfusion technologies and in-house media/process development and manufacturing expertise, HJB’s intensified continuous perfusion process can greatly increase viable cell culture density and maximizing specific production rate, leading to significantly improvements in both productivity and product quality. Additionally, the advanced perfusion platform maintains culture in a state of control at high viability, prolonging culture time and ensuring product quality throughout the culture period.
To date, HJB has successfully completed over 20 GMP production batches using working volumes of 50L, 100L, 200L, and 300L with continuous perfusion. By continuously advancing its capabilities in bioprocessing, HJB is committed to providing efficient, high-quality development and manufacturing solutions for its partners, helping bring more high-quality, accessible biopharmaceutical products to patients worldwide.